Kallmann Syndrome

DUBLIN, Oct. 24, 2022 /PRNewswire/ -- The "Male Hypogonadism Market By Drug Delivery, By Therapy, By Type: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering. The global male hypogonadism market was valued $ 3,072.86 million in 2020 and expected to reach $ 5,085.03 million by 2030, with a CAGR of 5.1% from 2021 to 2030. Hypogonadism is characterized as lack of testosterone level or lack of spermatozoa production, or both. It is caused owing to the disorder related to the testes (primary hypogonadism) or the hypothalamic-pituitary axis (secondary hypogonadism). Both can be inherited or acquired, due to ageing, hormonal disorders or medicines. In addition, various congenital enzyme abnormalities result in various degrees of androgen resistance in target organs. Hormone levels corroborate the diagnosis. The treatment for gonadotropin-releasing hormone, gonadotropin, or testosterone replacement differs depending on the aetiology. The factors that drive the global male hypogonadism market are increase in cases of hypogonadism, surge in awareness of hypogonadism, and rise in number of treatment options. In addition, hypogonadism is prevalent in the geriatric population as well as in patients with diabetes and obesity. As a result, increase in population and rise in the incidence and prevalence of chronic disorders, such as diabetes and obesity drive the growth of the market. According to clinical research, testosterone levels in males aged 60-80 years are 20 percent and 80 percent lower, respectively, than testosterone levels in young men. Hypogonadism is most common in men aged above 60. In countries like Japan, China, and the U.S. there is surge in demand for male hypogonadism treatments, owing to increase in geriatric population and surge in infertility rates. The male hypogonadism market is segmented on the basis of therapy, drug delivery, type, and region. Depending on therapy, it is divided into testosterone replacement therapy and gonadotropin & gonadotropin-releasing hormones therapy. The gonadotropin-releasing hormones therapy segment is segmented into luteinizing hormone (LH), follicle-stimulating hormone (FSH), human chorionic gonadotropin (HCG), and gonadotropin-releasing hormone (GNRH). According to drug delivery, it is fragmented into topical gels, injectable, transdermal patches, and others. As per the type, it is classified into Klinefelter's syndrome, Kallmann syndrome, pituitary disorders, and others. Region wise, it is analyzed across North America, Europe, Asia Pacific, and LAMEA. Major key players operating in the global male hypogonadism market are Allergan PLC., Bayer AG, Eli Lily & Company, Endo Iternational PLC., Ferring Holdings SA, Finox Biotech, Merck & Co. Inc., Pfizer, Perrigo Company PLC., Teva Pharmaceutical Industries Ltd. Key Benefits For Stakeholders This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the male hypogonadism market analysis from 2020 to 2030 to identify the prevailing male hypogonadism market opportunities. The market research is offered along with information related to key drivers, restraints, and opportunities. Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network. In-depth analysis of the male hypogonadism market segmentation assists to determine the prevailing market opportunities. Major countries in each region are mapped according to their revenue contribution to the global market. Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players. The report includes the analysis of the regional as well as global male hypogonadism market trends, key players, market segments, application areas, and market growth strategies. Key Topics Covered: CHAPTER 1: INTRODUCTION CHAPTER 2: EXECUTIVE SUMMARY CHAPTER 3: MARKET OVERVIEW 3.1. Market definition and scope 3.2. Key findings 3.2.1. Top investment pockets 3.3. Porter's five forces analysis 3.4. Top player positioning 3.5. Market dynamics 3.5.1. Drivers 3.5.2. Restraints 3.5.3. Opportunities 3.6. COVID-19 Impact Analysis on the market CHAPTER 4: MALE HYPOGONADISM MARKET, BY DRUG DELIVERY 4.1 Overview 4.1.1 Market size and forecast 4.2 Topical Gels 4.2.1 Key market trends, growth factors and opportunities 4.2.2 Market size and forecast, by region 4.2.3 Market analysis by country 4.3 Injectables 4.3.1 Key market trends, growth factors and opportunities 4.3.2 Market size and forecast, by region 4.3.3 Market analysis by country 4.4 Transdermal Patches 4.4.1 Key market trends, growth factors and opportunities 4.4.2 Market size and forecast, by region 4.4.3 Market analysis by country 4.5 Others 4.5.1 Key market trends, growth factors and opportunities 4.5.2 Market size and forecast, by region 4.5.3 Market analysis by country CHAPTER 5: MALE HYPOGONADISM MARKET, BY THERAPY 5.1 Overview 5.1.1 Market size and forecast 5.2 Testosterone Replacement Therapy 5.2.1 Key market trends, growth factors and opportunities 5.2.2 Market size and forecast, by region 5.2.3 Market analysis by country 5.3 Gonadotropin and Gonadotropin Releasing Hormone Therapy 5.3.1 Key market trends, growth factors and opportunities 5.3.2 Market size and forecast, by region 5.3.3 Market analysis by country CHAPTER 6: MALE HYPOGONADISM MARKET, BY TYPE 6.1 Overview 6.1.1 Market size and forecast 6.2 Klinefelters Syndrome 6.2.1 Key market trends, growth factors and opportunities 6.2.2 Market size and forecast, by region 6.2.3 Market analysis by country 6.3 Kallmann Syndrome 6.3.1 Key market trends, growth factors and opportunities 6.3.2 Market size and forecast, by region 6.3.3 Market analysis by country 6.4 Pituitary Disorders 6.4.1 Key market trends, growth factors and opportunities 6.4.2 Market size and forecast, by region 6.4.3 Market analysis by country 6.5 Others 6.5.1 Key market trends, growth factors and opportunities 6.5.2 Market size and forecast, by region 6.5.3 Market analysis by country CHAPTER 7: MALE HYPOGONADISM MARKET, BY REGION CHAPTER 8: COMPANY LANDSCAPE 8.1. Introduction 8.2. Top winning strategies 8.3. Product Mapping of Top 10 Player 8.4. Competitive Dashboard 8.5. Competitive Heatmap 8.6. Key developments CHAPTER 9: COMPANY PROFILES 9.1 Allergan plc 9.1.1 Company overview 9.1.2 Company snapshot 9.1.3 Operating business segments 9.1.4 Product portfolio 9.1.5 Business performance 9.1.6 Key strategic moves and developments 9.2 Pfizer Inc. 9.2.1 Company overview 9.2.2 Company snapshot 9.2.3 Operating business segments 9.2.4 Product portfolio 9.2.5 Business performance 9.2.6 Key strategic moves and developments 9.3 Bayer AG 9.3.1 Company overview 9.3.2 Company snapshot 9.3.3 Operating business segments 9.3.4 Product portfolio 9.3.5 Business performance 9.3.6 Key strategic moves and developments 9.4 Eli Lilly and Company Ltd. 9.4.1 Company overview 9.4.2 Company snapshot 9.4.3 Operating business segments 9.4.4 Product portfolio 9.4.5 Business performance 9.4.6 Key strategic moves and developments 9.5 Endo International plc. 9.5.1 Company overview 9.5.2 Company snapshot 9.5.3 Operating business segments 9.5.4 Product portfolio 9.5.5 Business performance 9.5.6 Key strategic moves and developments 9.6 Merck & Co., Inc. 9.6.1 Company overview 9.6.2 Company snapshot 9.6.3 Operating business segments 9.6.4 Product portfolio 9.6.5 Business performance 9.6.6 Key strategic moves and developments 9.7 Ferring 9.7.1 Company overview 9.7.2 Company snapshot 9.7.3 Operating business segments 9.7.4 Product portfolio 9.7.5 Business performance 9.7.6 Key strategic moves and developments 9.8 Finox Biotec 9.8.1 Company overview 9.8.2 Company snapshot 9.8.3 Operating business segments 9.8.4 Product portfolio 9.8.5 Business performance 9.8.6 Key strategic moves and developments 9.9 Teva Pharmaceutical Industries Ltd. 9.9.1 Company overview 9.9.2 Company snapshot 9.9.3 Operating business segments 9.9.4 Product portfolio 9.9.5 Business performance 9.9.6 Key strategic moves and developments 9.10 Perrigo Company plc 9.10.1 Company overview 9.10.2 Company snapshot 9.10.3 Operating business segments 9.10.4 Product portfolio 9.10.5 Business performance 9.10.6 Key strategic moves and developments For more information about this report visit Logo - Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets

Researchers have discovered a potential treatment target for Down syndrome, Th17 cells could mitigate microbiome-linked diseases and electroacupuncture shows promise in the treatment of Parkinson's disease. New Potential Target for Down Syndrome Researchers have found a potential treatment target for cognitive deficits in patients with Down syndrome. Altered gonadotropin-releasing hormone (GnRH) secretion in patients with similar diseases, like Kallmann syndrome, presents as olfactory defects, gonadal immaturity and infertility. In the case of hypothalamic GnRH, there are projections to areas of the brain involved in intellectual functioning as well. Due to the symptom overlap, the researchers hypothesized that the maturation of the GnRH system may impact Down syndrome (DS). To test this, they used a trisomic mouse model that displayed similar characteristics to humans with DS. The researchers were able to manipulate the microRNA involved in the GnRH developmental switch. When they did this, they saw an abolishment of altered gene expression as well as deficits in neuronal activity, olfaction and cognition. With these promising results, the researchers moved on to a pilot study where they tested this process on human patients with DS. The treatment was found to be safe and is currently being used to treat patients with Kellman’s syndrome. Over the course of six months of pulsatile GnRH treatment, the patients showed improvement in cognitive performance and functional brain activity. It appears that the GnRH system plays a developmental role in brain maturation and higher-order functioning, and therapy for the hormonal pathway may play an important part in the improvement of cognitive deficits in DS. Depletion of Th17 Cells could Mitigate Microbiome-Linked Diseases Researchers have discovered a contributing factor as to why high-sugar, high-fat diets may hurt the gut microbiome. The gut microbiome is the system of bacteria that lives in the gastrointestinal tract. The microbiota in the gut are correlated to and thought to regulate metabolic syndromes, but how they do so is not completely understood. In the study led by Columbia University, the researchers showed that the intestinal microbiome protects against the development of obesity, metabolic syndrome and pre-diabetes by inducing Th17 cells. High levels of fat and sugar contribute to the depletion of Th17 cells. It is known that Th17 cells are what help protect us from metabolic syndromes. Therefore, the researchers hypothesize that this diet-induced depletion of Th17 cells is a linking factor between diet and microbiome-linked diseases. They expressed optimistic that this information can be used for future studies to help prevent such diseases from developing in the first place. Using Electroacuppuncture to Treat Parkinson’s Disease Researchers succeeded in using scalp-abdominal electroacupuncture as a supplementary treatment for Parkinson’s Disorder (PD). The randomized and controlled study examined electroacupuncture targeting the gut-brain axis. The researchers found PD patients who received electroacupuncture rather than their typical drug treatment showed marked improvement in their PD symptoms. The control group, which continued with their usual drug treatments, had expected results with little worsening and little improvement. After 8 weeks of scalp-abdominal electroacupuncture, PD patients had improved motor and non-motor PD symptoms, though there was no change in their disease stage. Based on these results, the researchers concluded that electroacupuncture treatments may be useful not just on their own in early-stage patients, but also in conjunction with typical drug treatments in later-stage patients. Blood Cancer Patients Generate Specialized T cells Against SARS-COV-2 In a new study from The Leukemia & Lymphoma Society, researchers report that blood cancer patients who don’t produce detectable antibodies after COVID-19 vaccination may have T cells specialized to protect against the virus. Findings from the LLS National Patient Registry showed that 45% of blood cancer patients who had no detectable antibodies after full vaccination generated these specialized T-cells. Instead of preventing infection in the first place, these T-cells work to attack the virus once it has taken root inside cells, they found. Newly Identified Biomarkers can Predict Onset and Severity of Eczema Researchers led by Dr. Anne-Sofie Halling at Bispebjerg Hospital at the University of Copenhagen have discovered an immune biomarker in newborns that can predict the onset and severity of pediatric atopic eczema. The study analyzed 450 babies to examine whether skin barrier and immune biomarkers could predict the onset and severity of eczema during the first two years of life. The researchers found that babies with elevated levels of Thymus and Activation-Regulated Chemokine (TARC) at two months were more than twice as likely to develop eczema by the age of two. This risk was still present after adjusting for mediating factors, such as parental atopy (when the immune system is more sensitive to allergic diseases) and filaggrin gene mutations, both predispositions for eczema. The test is painless and easy to perform and Halling said there is a “window of opportunity to develop targeted trials and prevent cases of eczema from occurring.”

Hypogonadism in males refers to a condition in the male body where the testes show a significantly reduced level of functioning than normal. The overall result of male hypogonadism is a reduction in the rate of biosynthesis of male sex hormones. This state is more commonly known as interrupted stage 1 puberty. Hypoandrogenism, or the low androgen or testosterone level in a male can vary in severity from person to person. It is often the cause of partial or complete infertility. There are multiple forms of male hypogonadism and even more ways to classify them. Most endocrinologists commonly classify male hypogonadism on the basis of the level of defectiveness of the male reproductive system. In many cases, doctors also measure the level of gonadotropins to classify a patient between primary and secondary male hypogonadism. Primary male hypogonadism refers to the cause of the condition being due to defective gonads. There are different types of primary male hypogonadism, including Turner syndrome and Klinefelter syndrome. Secondary male hypogonadism is caused by defects in pituitary or hypothalamic glands. They include Kallmann syndrome and hypopituitarism. Global Male Hypogonadism Market: Overview Male Hypogonadism refers to a clinical condition, wherein the testes fail to produce enough testosterone leading to delayed puberty or incomplete development. The condition is related to impaired development of muscle mass, development of breast tissues, impaired body hair growth, and lack of deepening of the voice. The male Hypogonadism market can be segmented by therapy, type, drug delivery, and geography. The report presents an in-depth analysis of the global male hypogonadism market with current trends and future estimates to explain the imminent investment pockets. The quantitative analysis of the market for the forecast period from 2017 to 2025 will enable stakeholders to capitalize on the prevailing growth opportunities. GET BROCHURE OF THE REPORT Global Male Hypogonadism Market: Trends and Opportunities The top driver of the male hypogonadism market includes rising prevalence of testosterone deficiency among men, increasing infertility rates, and increasing awareness among individuals about hypogonadism treatment due to awareness drives organized by several governments across the world. Moreover, high risk of hypogonadism among the geriatric population with obesity and diabetes, and increasing prevalence of chronic disorders among the geriatrics are further expected to boost the market’s growth. However, factors such as high side effects of testosterone products are challenging the growth of testosterone replacement therapy market. Top players in the market are focused on research and development to introduce newer products with fewer or negligible side effects and improved results. For example, LPCN 1111, a product which is under development from Lipocine Inc., is a newer testosterone prodrug that utilizes Lip’ral technology for enhanced systemic absorption and for enhanced solubility of testosterone. Nevertheless, technological advancements are anticipated to extend new opportunities to the market’s growth. GET TABLE OF CONTENT OF THE REPORT Global Male Hypogonadism Market: Regional Overview The global male Hypogonadism market can be analyzed with respect to the regional segments of North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. North America held the majority share of the global market in the recent past and is expected to retain its dominant position in the near future. This is mainly due to the rise in the number of individuals suffering from primary and secondary conditions of hypogonadism, and rising awareness among individuals about treatment options for the condition. Moreover, the presence of ultra-modern healthcare infrastructure and increasing popularity of technologically advanced products are expected to offer new opportunities for top players in this market. The region is closely followed by Europe. Asia Pacific is expected to offer lucrative opportunities to this market due to the modernization of the healthcare infrastructure in the emerging economies of India and China and the increasing awareness about the treatment for the condition. In Asia Pacific, the increasing prevalence of hypogonadism and infertility rates along with the rising geriatric population base with diabetes and obesity are propelling the growth of this market. China, Taiwan, and Malaysia are some of the countries that display the highest rate of male hypogonadism. Major Companies Mentioned in Report Some of the key players in the male Hypogonadism market include AbbVie Inc., Astrazeneca plc, Eli Lilly and Company Ltd., Merck & Co. Inc., SA, Finox Biotech, Laboratories Genevrier, Teva Pharmaceutical Industries Ltd., Allergan plc, Bayer AG, Endo International plc, IBSA Institut Biochimque, and Ferring. Key players are focused on product approval for growth considerations and to cater to the changing demand of the industry. The introduction of innovative and technologically advanced products is also the focus of key players to increase their market share and for serving patients in a better manner. GET DISCOUNT ON THE LATEST REPORT TMR Research has rich experience in developing state-of-the-art reports for a wide array of markets and sectors. The brilliance of the experts at TMR Research and their alacrity to conduct thorough research and create phenomenal reports makes TMR Research better than others. 5-Point Growth Formula The 5-point growth formula developed by TMR Research provides an insight to the stakeholders and CXOs about the current situation in the market. The growth formula makes the report a perfect companion for the stakeholders and CXOs. The 5-point growth formula includes the following points: Current and Future Threats Accurate Trend Analysis Regional Assessment Industrial Analogy COVID-19 Impact Current and Future Threats Along with studying the opportunities necessary for growth, threats are also an important aspect to look upon for the companies and stakeholders in a specific sector. TMR Research studies every negative aspect that will hinder the growth of a specific area of business and includes it in the report. The stakeholders and CXOs will have the benefit of assessing the threat and take the necessary steps to prevent the hindrance caused due to the threats. Accurate Trend Analysis Keeping up with the latest trends is crucial in any business or sector. While stakeholders are aware of the trends that are on the surface, TMR Researchers find trends that are deeply entrenched in the particular market or sector. The reports are constantly updated with the latest trends so that the stakeholders and CXOs can derive benefits from the trends and generate good revenues. Regional Assessment Demography forms an important part of the growth pattern of all the markets. Diving deep into the demographics enables maximum output from specific areas. The TMR Research team assesses every region and picks out the vital points that have a large impact on the growth of a market. Industrial Analogy The analysts at TMR Research conduct an all-round analysis on the competitive landscape of the market. The observations recorded by the analysts are added to the reports so that every stakeholder gets a glimpse of the competitive scenario and frame their business plans according to the situation. COVID-19 Impact The COVID-19 outbreak has changed the growth projections of numerous sectors and businesses. The analysts at TMR Research have conducted a conscientious survey on the markets after the pandemic struck. The analysts have put forth their brilliant and well-researched opinions in the report. The opinions will help the stakeholders to plan their strategy accordingly. The reports offer answers to the top 7 questions that revolve around the growth of the market What are the diverse growth parameters influencing the market? Which regions will contribute largely to the growth of the market What are the recent innovations and technological advancements in the market? What are the emerging trends across the market? How has COVID-19 affected the market? What will be the post-pandemic scenario of the market? What are the major threats that will dent the growth prospects of the market? About TMR Research TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends. Contact: Rohit Bhisey TMR Research, 3739 Balboa St # 1097, San Francisco, CA 94121 United States Tel: +1-415-520-1050 Visit Site: